The single-use molecular test identifies the RNA of the virus that causes COVID-19 from a nasal swab sample in 25 minutes. The analysis is conducted at the point of care and results are transmitted to Cue’s health app.
The FDA presently allows the tests to take place only under the supervision of licensed medical staff, but Cue is working toward receiving authorization for use in schools, workplaces and homes.
More articles on digital transformation:
Virtual ICUs return stolen moments between patients and loved ones
Only 12% of CFOs expect to cut, defer digital transformation spending: survey
QR codes can help patients recall information from their doctors, study suggests
